Glaukos gets FDA nod for iDose TR re-administration
January 28, 2026
Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR system.
Glaukos (NYSE:GKOS) announced today that the FDA approved a new drug application (NDA) labeling supplement for its iDose TR system.
Large study of patients in U.S., Colombia, Nigeria and India finds symptom burden highest in high-income countries
Olympus today announced the U.S. launch of its most advanced single-use fine needle biopsy device.
eMurmur has received FDA 510(k) clearance for its next-generation heart murmur detection software, eMurmur Heart AI (2.2).